Moderna's mRNA-based flu vaccine, mFLUSIVA (mRNA-1010), is facing a pivotal moment with the U.S. Food and Drug Administration (FDA) advisory committee, marking a significant step in the expansion of mRNA technology beyond COVID-19. This development unfolds against a backdrop of dynamic shifts within the biopharma industry, characterized by a surge in initial public offerings (IPOs) alongside substantial workforce reductions at established pharmaceutical companies. The journey for Moderna's seasonal mRNA flu shot has been notably tumultuous.